Erlotinib hydrochloride CAS NO.183319-69-9

Min.Order Quantity:: 100 Gram

Purity:: 99%

Port:: Qingdao,China

Payment Terms:: L/C,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

183319-69-9 factory in China
Erlotinib hydrochloride factory in China
183319-69-9 seller in China

Quick Details

ProName: Erlotinib hydrochloride
CasNo: 183319-69-9
Molecular Formula: C22H24ClN3O4
Appearance: white powder
Application: 1. Erlotinib hydrochloride is a kind o...
DeliveryTime: Within7-10 days after receipt of your ...
PackAge: As customer request
Port: Qingdao,China
ProductionCapacity: 100 Kilogram/Month
Purity: 99%
Storage: Store in a cool,dry place and keep awa...
Transportation: Common products:Sea/Air/Courier ...
LimitNum: 100 Gram
MW:: 429.9
Mol File:: 183319-69-9.mol
Melting point: 223-225°C

Superiority

triumph chemical title

triumph company office picture

triumph company advantage

triumph testing title picture

triumph testing way

welcome to contact us

lorcaserin(856681-05-5)is an orally administered agent and a selective 5-ht2c receptor agonist for the treatment of obesity. it had been approved for marketing in us by fda on 27 june in 2012. in clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.

Details

details

cas no.	183319-69-9
	erlotinib hcl

	c22h23n3o4.hcl
	429.9
	98%
	can supply large quantity in kgs scale
alias	tarceva;cp-358774;cp 358774;cp358774;osi-774;osi 774;osi774;nsc-718781;nsc 718781;nsc718781
product brief introduction	erlotinib is a directly acting inhibitor of human egfr tyrosine kinase with an ic50 of 2 nm.
detailed description:	erlotinib hcl potently inhibits egfr activation in intact cells including hns human head and neck tumor cells (ic50 20nm), difi humancolon cancer cells andmda mb-468 human breast cancer cells. erlotinib hcl (1 μm) induces apoptosis in difi humancolon cancer cells.erlotinib inhibits growth of a panel of nsclc cell lines including a549, h322, h3255, h358 h661, h1650, h1975, h1299, h596 with ic50 ranging from 29 nm to >20 μm.erlotinib hcl(2 μm) significantly inhibits growth of aspc-1 and bxpc-3 pancreatic cells.the effects of erlotinib hcl in combination with gemcitabine are considered additive in kras-mutated pancreatic cancer cells. ten micromolar of erlotinib hcl inhibits egfr phospho-rylation at the y845 (src-dependent phosphorylation) and y1068 (auto-phosphorylation) sites. combination with erlotinib hcl could down-modulate rapamycin-stimulated akt activity and produces a synergistic effect on cell growth inhibition.